MedTrace Logo

Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery

NCT01994330 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2017-04-05

No results posted yet for this study

Summary

Acquired Von Willebrand disease (type 2A) has been described in patients with severe aortic stenosis, the association of aortic stenosis and Digestive bleeding due to this phenomena has received the name of Heye´s syndrome.

We propose that administering Desmopressin (DDAVP) in patients scheduled to aortic valve replacement surgery will reduce blood loss and transfusion rate.

this was a pilot study

Conditions

  • Acquired Von Willebrand Disease Secondary to Severe Aortic Stenosis
  • Heye´s Syndrome
  • Severe Aortic Stenosis

Interventions

DRUG

desmopressin

0.3 mcg per kilogram administered in 30 minutes a half hour previous to surgical incision

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    collaborator INDUSTRY

  • Pontificia Universidad Catolica de Chile

    lead OTHER

Principal Investigators

  • esperanza carrasco, anesthesiologist · Pontificia Universidad Catolica de Chile

  • rodrigo lopez, anesthesiologist · Pontificia Universidad Catolica de Chile

  • guillermo lema, profesor titular · Pontificia Universidad Catolica de Chile

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-12-31
Completion
2010-02-28

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01994330 on ClinicalTrials.gov